Skip to main content
Accueil
  • fr
  • en

Main navigation

  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers
Menu

Third quarter 2025 Financial Results and Business Updates | November 13, 2025


Press Release and Webcast

In-person & virtual event - Lacutamab: a Phase 3-ready asset


Access the replay

Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma


More about our lead asset

IPH4502, our Antibody Drug Conjugate targeting Nectin-4


More about this asset

Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca


More about this asset

Collaborating with a strong network to advance our pipeline


Discover our partnering opportunities

Previous Next

About Innate Pharma

#TheFutureIsInnate

Innate Pharma is a global clinical-stage oncology-focused biotech company. Our ambition is to establish innovative approaches to make a lasting difference to patients’ lives by providing drugs based on therapeutic antibodies that harness the immune system.

See company profile

Latest news

Innate Pharma announces conference call and webcast for Third quarter 2025 results and business updates

November 5, 2025

Innate Pharma to host analyst and investor event on lacutamab on October 28, 2025

October 14, 2025

Innate Pharma Reports First Half 2025 Business Update And Financial Results

September 17, 2025
See all press releases

Footer

  • Contact
  • Location
  • Site map
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookies notice
  • General Conditions of Purchase

Follow us

   

Stay in touch

 Subscribe to our newsletter

 Contact us
 

Location

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

 +33 (0)4 30 30 30 30

 Innate Pharma, Inc.
2273 Research Boulevard, Suite 350
Rockville, MD 20850, USA

Innate Pharma
  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers